Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial.

Daisuke ItoSatoshi ShimizuKazuyuki InoueDaigo SaitoMorifumi YanagisawaKouichi InukaiYuji AkiyamaYoshihiro MorimotoMitsuhiko NodaAkira Shimada

Published in: Diabetes care (2017)

Compared with pioglitazone, ipragliflozin exerts equally beneficial effects on NAFLD and glycemic control during the treatment of patients with type 2 diabetes complicated by NAFLD. Furthermore, ipragliflozin significantly reduced body weight and abdominal fat area.

Keyphrases

body weight
glycemic control
open label
type diabetes
blood glucose
clinical trial
study protocol
adipose tissue
weight loss
phase ii study
phase iii
insulin resistance
randomized controlled trial
metabolic syndrome
replacement therapy